List To Watch: SolarCity Corporation (NASDAQ:SCTY), Valley National Bancorp (NYSE:VLY), Discovery Laboratories (NASDAQ:DSCO), Arrowhead Research Corp. (NASDAQ:ARWR)

RPX Corporation (NASDAQ:RPXC) shares fell -0.55% in last trading session and ended the day at $10.85. RPXC Gross Margin is 50.20% and its has a return on assets of 6.40%. RPX Corporation (NASDAQ:RPXC) quarterly performance is -23.48%.

RPX Corporation (NASDAQ:RPXC) released its 2015 NPE Activity: Highlightsreport-a first look at trends in patent litigation activity for 2015. NPE litigation activity rebounded in 2015 following what now appears to have been a slowdown in the latter half of 2014.

On 05 January, SolarCity Corporation (NASDAQ:SCTY) shares decreased -4.45% and was closed at $50.44. SCTY EPS growth in last 5 year was 28.10%. SolarCity Corporation (NASDAQ:SCTY) year to date (YTD) performance is -1.14%.

SolarCity Corporation (NASDAQ:SCTY) CEO Lyndon Rive called the new changes, which would take effect Jan. 1, and would retroactively apply to the state’s 12,000 solar owners, “unethical, unprecedented, and possibly unlawful.

Valley National Bancorp (NYSE:VLY) shares decreased -0.10% in last trading session and ended the day at $9.55. VLY has a return on assets of 0.60%. Valley National Bancorp (NYSE:VLY) quarterly performance is -2.47%.

Valley National Bancorp (NYSE:VLY) announced that it will release its fourth quarter 2015 earnings before the market opens on Wednesday, January 27, 2016.

Discovery Laboratories Inc. (NASDAQ:DSCO) caters to the Healthcare space. Its weekly performance is -8.78%. On the last day of trading company shares ended up at $0.21. Discovery Laboratories Inc. (NASDAQ:DSCO) distance from 50-day simple moving average (SMA50) is 0.06%.

On 29 December, Discovery Laboratories Inc. (NASDAQ:DSCO) announced that it has initiated its AEROSURF® phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS). The trial is designed to evaluate premature infants receiving aerosolized KL4 surfactant (including potentially repeat doses) compared to nCPAP alone. Two dose groups will be evaluated. The primary objective of the trial is to demonstrate evidence of efficacy and, if successful, inform the design of a phase 3 clinical program.

Arrowhead Research Corp. (NASDAQ:ARWR) caters to the Healthcare space. Its weekly performance is -5.17%. On the last day of trading company shares ended up at $5.87. Arrowhead Research Corp. (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -1.02%.

Arrowhead Research Corp. (NASDAQ:ARWR) said that, provides an overview of the Arrowhead Research Corporation ’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Arrowhead Research Corporation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.